Motavizumab

BIOLOGICAL7 trials

Sponsors

MedImmune LLC

Conditions

Chronic Lung Disease and <= 24 Months of Age orCongenital Heart DiseaseHealthyParticipants Less Than 12 Months of Age With RSV IllnessPremature With Gestational Age <=35 Weeks and <=6 Months of AgeRSV Illness in ≤12 Months of ParticipantsRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus Prophylaxis

Phase 1

Safety Study of a Monoclonal Antibody to Respiratory Syncytial Virus (RSV) in Children Hospitalized With RSV Infection

CompletedNCT00192504

MedImmune LLCRespiratory Syncytial Virus Prophylaxis

Start: 2004-03-31End: 2005-01-31Updated: 2021-10-08

Phase 2

Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season

CompletedNCT00316264

MedImmune LLCChronic Lung Disease and <= 24 Months of Age or, Premature With Gestational Age <=35 Weeks and <=6 Months of Age, Respiratory Syncytial Virus Infections

Start: 2006-04-30End: 2007-02-28Updated: 2012-12-11

A Study to Evaluate a Single Intramuscular Dose of Motavizumab to Treat Children With Respiratory Syncytial Virus (RSV) Illness

TerminatedNCT00435227

MedImmune LLCParticipants Less Than 12 Months of Age With RSV Illness

Start: 2007-03-20End: 2008-05-31Updated: 2021-08-17

A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease

CompletedNCT00538785

MedImmune LLCCongenital Heart Disease

Start: 2005-10-31End: 2008-06-30Updated: 2012-02-16

Phase 3

MEDI-524 (Motavizumab) for the Prevention of Respiratory Sycytial Virus (RSV) Disease Among Native American Indian Infants in the Southwestern United States

CompletedNCT00121108

MedImmune LLCHealthy

Start: 2004-11-15End: 2010-12-27Updated: 2022-01-05

A Phase 3 Trial of the Effect of Motavizumab Prophylaxis on Reduction of Serious Early Childhood Wheezing in Infants

WithdrawnNCT00628303

MedImmune LLCWheezing

Start: 2010-10-31End: 2011-12-31Updated: 2012-08-01

Unknown Phase

A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment of Children Hospitalized With Respiratory Syncytial Virus (RSV) Illness

CompletedNCT00421304

MedImmune LLCRSV Illness in ≤12 Months of Participants

Start: 2007-01-10End: 2009-09-17Updated: 2021-08-27

Related Papers

Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial.

2015-11-04141 citations

A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season.

2010-06-0334 citations